Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2006 1
2008 1
2009 1
2010 1
2011 1
2015 2
2016 3
2017 6
2018 2
2019 1
2020 2
2021 2
2022 5
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding.
Spodzieja M, Kuncewicz K, Sieradzan A, Karczyńska A, Iwaszkiewicz J, Cesson V, Węgrzyn K, Zhukov I, Maszota-Zieleniak M, Michielin O, Speiser DE, Zoete V, Derré L, Rodziewicz-Motowidło S. Spodzieja M, et al. Among authors: cesson v. Int J Mol Sci. 2020 Jan 18;21(2):636. doi: 10.3390/ijms21020636. Int J Mol Sci. 2020. PMID: 31963646 Free PMC article.
Intramuscular Immunization Induces Antigen-specific Antibodies in Urine.
Derré L, Lucca I, Cesson V, Valerio M, Cerantola Y, Burruni R, Fritschi U, Gharbi D, Bobst M, Legris AS, Dartiguenave F, Jichlinski P, Nardelli-Haefliger D. Derré L, et al. Among authors: cesson v. Eur Urol Focus. 2020 Mar 15;6(2):280-283. doi: 10.1016/j.euf.2018.09.003. Epub 2018 Sep 13. Eur Urol Focus. 2020. PMID: 30219710
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.
Derré L, Lucca I, Cesson V, Bohner P, Crettenand F, Rodrigues-Dias SC, Dartiguenave F, Masnada A, Teixeira-Pereira C, Benmerzoug S, Chevalier MF, Domingos-Pereira S, Nguyen S, Polak L, Schneider AK, Jichlinski P, Roth B, Nardelli-Haefliger D. Derré L, et al. Among authors: cesson v. J Immunother Cancer. 2023 Dec 14;11(12):e008020. doi: 10.1136/jitc-2023-008020. J Immunother Cancer. 2023. PMID: 38101861 Free PMC article.
Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
Benmerzoug S, Chevalier MF, Verardo M, Nguyen S, Cesson V, Schneider AK, Dartiguenave F, Rodrigues-Dias SC, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Benmerzoug S, et al. Among authors: cesson v. Eur Urol Focus. 2022 May;8(3):748-751. doi: 10.1016/j.euf.2021.06.001. Epub 2021 Jun 17. Eur Urol Focus. 2022. PMID: 34147404 Free article.
Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile.
Lucca I, Derré L, Cesson V, Bohner P, Crettenand F, Rodrigues-Dias S, Dartiguenave F, Masnada A, Texeira-Pereira C, Benmerzoug S, Chevalier M, Domingos-Pereira S, Nguyen S, Polak L, Schneider A, Roth B, Jichlinski P, Nardelli-Haefliger D. Lucca I, et al. Among authors: cesson v. Eur Urol Open Sci. 2022 Oct 3;45:55-58. doi: 10.1016/j.euros.2022.09.004. eCollection 2022 Nov. Eur Urol Open Sci. 2022. PMID: 36212980 Free PMC article.
Identification of Urine Biomarkers to Improve Eligibility for Prostate Biopsy and Detect High-Grade Prostate Cancer.
Alijaj N, Pavlovic B, Martel P, Rakauskas A, Cesson V, Saba K, Hermanns T, Oechslin P, Veit M, Provenzano M, Rüschoff JH, Brada MD, Rupp NJ, Poyet C, Derré L, Valerio M, Banzola I, Eberli D. Alijaj N, et al. Among authors: cesson v. Cancers (Basel). 2022 Feb 23;14(5):1135. doi: 10.3390/cancers14051135. Cancers (Basel). 2022. PMID: 35267445 Free PMC article.
Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate Cancer.
Ahmed R, Lozano LE, Anastasio A, Lofek S, Mastelic-Gavillet B, Navarro Rodrigo B, Nguyen S, Dartiguenave F, Rodrigues-Dias SC, Cesson V, Valério M, Roth B, Kandalaft LE, Redchenko I, Hill AVS, Harari A, Romero P, Derré L, Viganó S. Ahmed R, et al. Among authors: cesson v. Cancers (Basel). 2023 Jun 8;15(12):3114. doi: 10.3390/cancers15123114. Cancers (Basel). 2023. PMID: 37370724 Free PMC article.
Type 2 innate lymphoid cells are not involved in mouse bladder tumor development.
Schneider AK, Domingos-Pereira S, Cesson V, Polak L, Fallon PG, Zhu J, Roth B, Nardelli-Haefliger D, Derré L. Schneider AK, et al. Among authors: cesson v. Front Immunol. 2024 Jan 12;14:1335326. doi: 10.3389/fimmu.2023.1335326. eCollection 2023. Front Immunol. 2024. PMID: 38283350 Free PMC article.
Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.
Benmerzoug S, Chevalier MF, Villier L, Nguyen S, Cesson V, Schneider AK, Dartiguenave F, Rodrigues-Dias SC, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Benmerzoug S, et al. Among authors: cesson v. Eur Urol Open Sci. 2021 Nov 18;34:79-82. doi: 10.1016/j.euros.2021.10.001. eCollection 2021 Dec. Eur Urol Open Sci. 2021. PMID: 34825225 Free PMC article.
27 results